Insider · CIK 0001839163
Jeffrey Chi
Files at AARD (Aardvark Therapeutics, Inc.). First filing -, latest -.
In brief
Jeffrey Chi files SEC Form 4 as director at AARD (Aardvark Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey Chi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | AARD Aardvark Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +44,964 | $0.00 | $0 | 44,964 | Aug 21, 2026 |
| Jun 11, 2025 | AARD Aardvark Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +61,017 | $0.00 | $0 | 61,017 | Jun 13, 2025 |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | CConversion Common Stockindirect: By Vickers Venture Co-investment LLC | +133,364 | - | - | 133,364 | Feb 19, 2025 |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivativeindirect: By Vickers Venture Co-investment LLC | -1,130,135 | $0.00 | $0 | 0 | Feb 19, 2025 |
Questions about Jeffrey Chi
Answered from the filings on this page, as of the latest one.
Is Jeffrey Chi buying or selling?
Jeffrey Chi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey Chi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Chi has 0.
Where does Jeffrey Chi file Form 4?
Jeffrey Chi has filed Form 4 at AARD (Aardvark Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.